在 COVID-19 大流行期间日本肾素-血管紧张素系统抑制剂的处方：中断时间序列研究。
Prescription of renin-angiotensin system inhibitors in Japan during the COVID-19 pandemic: interrupted time series study.
机构信息
Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, 1-12-1 Fukumuro, Miyagino-ku, Sendai, Miyagi, 983-8512, Japan.
Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, 1-12-1 Fukumuro, Miyagino-ku, Sendai, Miyagi, 983-8512, Japan.
出版信息
Hypertens Res. 2023 Dec;46(12):2593-2602. doi: 10.1038/s41440-023-01373-0. Epub 2023 Jul 18.
We surveyed changes in angiotensin-converting enzyme inhibitor (ACEIs) and angiotensin II receptor blocker (ARBs) prescription trends during the coronavirus disease 2019 (COVID-19) pandemic in Japan. Data of 1,605,708 outpatients with hypertension were extracted from the Medical Data Vision database. Trends for prescription of ACEIs and ARBs were assessed by analyzing the proportion of these prescriptions in each month, between April 2018 and November 2020. The proportion of ARBs prescriptions changed significantly in trend between the peri-pandemic and pre-pandemic periods (-0.05%/month, P = 0.012). In contrast, the proportion of ACEIs prescriptions did not change significantly in trend in the peri-pandemic period (0.01%/month, P = 0.189). There was no suggestion that the prescribing of ACEIs and ARBs was affected by the COVID-19 pandemic.
我们调查了在 2019 年冠状病毒病（COVID-19）大流行期间日本血管紧张素转换酶抑制剂（ACEI）和血管紧张素 II 受体阻滞剂（ARB）处方趋势的变化。从 Medical Data Vision 数据库中提取了 1605708 名高血压门诊患者的数据。通过分析每个月 ACEI 和 ARB 的处方比例，评估 ACEI 和 ARB 的处方趋势。在大流行前后期间，ARB 处方的比例在趋势上发生了显著变化（每月-0.05%，P=0.012）。相比之下，在大流行期间 ACEI 处方的比例在趋势上没有发生显著变化（每月 0.01%，P=0.189）。没有迹象表明 ACEI 和 ARB 的处方受到 COVID-19 大流行的影响。
Zotero 插件